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Sialylation is a biosynthetic process occurring in the trans
compartments of the Golgi apparatus. Corresponding evi-
dence is based on localization and biochemical studies of
α2,6(N)-sialyltransferase (ST6Gal I) as previously reported.
Here we describe generation and characterization of poly-
clonal antibodies to recombinant rat α2,3(N)-sialyltransfer-
ase (ST3Gal III) expressed as a soluble enzyme in Sf9 cells or
as a β-galactosidase-human-ST3Gal III fusion-protein from
E.coli, respectively. These antibodies were used to localize
ST3Gal III by immunofluorescence in various cell lines and
rat kidney tissue sections. In transiently transfected COS cells
the antibodies directed to soluble sialyltransferase or the
sialyltransferase portion of the fusion-protein only recog-
nized the recombinant antigen retained in the endoplasmic
reticulum. However, an antibody fraction crossreactive with
β-galactosidase recognized natively expressed ST3Gal III
which was found to be colocalized with β1,4-galactosyl-
transferase in the Golgi apparatus of several cultured cell
lines. Antibodies affinity purified on the β-galactosidase-
ST3Gal III fusion-protein column derived from both antisera
have then been used to localize the enzyme in perfusion-fixed
rat kidney sections. We found strong staining of the Golgi
apparatus of tubular epithelia and a brush-border-associated
staining which colocalized with cytochemical staining of the
H+ATPase. This subcellular localization was not observed for
ST6Gal I which localized to the Golgi apparatus. These data
show colocalization in the Golgi apparatus and different post-
Golgi distributions of the two sialyltransferases.
Key words: α2,3(N)-sialyltransferase/β-galactosidase/Golgi
apparatus/kidney tubules/Jurkat cells
Introduction
Glycosyltransferases comprise a large group of enzymes involved
in the synthesis of complex carbohydrates of glycoproteins,
glycolipids and glycosaminoglycans. The enzymes are membrane-
bound and localized predominantly to the Golgi apparatus and the
trans Golgi network (TGN). In many cell types glycosyltrans-
ferases seem to be restricted to Golgi subcompartments (Roth,
1987). According to a widely accepted scheme, early acting Golgi
glycosyltransferases are located in cis cisternae whereas late acting
enzymes are mainly found in the trans Golgi or the TGN (for
reviews, see Berger, 1985; Dunphy and Rothman, 1985; Farquhar,
1985). Galactose and sialic acid belong to the outer chains of
N-linked carbohydrates; therefore, the respective enzymes galacto-
syl- and sialyltransferases are expected to be located in the trans
Golgi and TGN. This location was confirmed by immunoelectron
microscopy (Roth and Berger, 1982; Roth et al., 1985) and by
colocalization of β1,4-galactosyltransferase (β1,4-GT) with
α2,6(N)-sialyltransferase (ST6Gal I) in conventional (Taatjes et
al., 1987) and confocal double immunofluorescence microscopy
(Berger et al., 1995). More recent reports suggested a less rigid
confinement of glycosyltransferases since overlapping distribu-
tions of the different enzymes in the Golgi apparatus have been
observed (Nilsson et al., 1993; Rabouille et al., 1995; for review,
see also Rabouille and Nilsson, 1995). In addition, the distribution
patterns of glycosyltransferases and processing enzymes seem to
be cell-type specific (Roth et al., 1986; Velasco et al., 1993).
Finally, there are reports about post-Golgi localizations of
glycosyltransferases: While β1,4-GT has been postulated to be
expressed at the cell surface since many years (Cooke and Shur,
1994), one report also showed a plasma membrane association of
ST6Gal I by using protein-specific antibodies (Taatjes et al., 1988).
These findings raise the question whether glycosyltransferases are
confined to their canonical Golgi localization or whether they can
be targeted to post-Golgi sites. In the majority of cultured cell lines,
glycosyltransferases are confined to the Golgi apparatus which
appears as a compact juxtanuclear structure (Berger et al., 1981).
Cell surface expression of native glycosyltransferases in cultured
cells are extremely uncommon; however, when transiently overex-
pressed in transfected cells they can be readily detected, as recently
shown in the case of α1,3-fucosyltransferase V (Borsig et al.,
1996). Little is known on glycosyltransferase localization in tissue
specimens. The histoarchitecture of tissues which affords an
entirely different environment to the cells than growth in
monolayers also modifies the shape of the Golgi apparatus (Taatjes
et al., 1987) and thereby may rearrange the localization of
glycosyltransferases. Thus, localization studies conducted in tissue
sections may unravel new sites that would not be anticipated from
studies in cultured cells.
Since the introduction of cloning techniques to glycosyltrans-
ferase enzymology, powerful methods to delineate their organo-
typic expression are available such as Northern blots and in situ
hybridization. However, Northern blots usually rely on crude
RNA extracts from entire organs, which affords at best a rough
orientation on the predominant expression sites. In situ hybridiza-
tion may be useful to identify the cell types expressing a particular
glycosyltransferase but would not address the question of its
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Fig. 1. Schematic view of ST3Gal III sequences. (a) Scheme of the rat ST3Gal III protein sequence with the cytoplasmic N-terminus; the transmembrane domain
(dark bar); the luminal, catalytically active C-terminus; two conserved regions among sialyltransferases referred to as “sialyl-motifs (gray bars) and two potential
N-glycosylation sites (Kitagawa et al., 1993). (b) Corresponding DNA sequence of ST3Gal III with the XhoI restriction site and the position of the observed
deletion from bp 120 to 167. (c) ST3Gal III DNA sequence of the PCR-cloned form from Jurkat cells that was introduced into the expression vector which was
used for the production of the β-galactosidase-ST3Gal III fusion-protein. (d) cDNA encoding truncated (broken line) soluble rat ST3Gal III used for expression in
Sf9 cells using the baculovirus expression system.
subcellular localization. Thus, protein-specific antibodies for
glycosyltransferases remain the tools of choice to address
problems related to both tissular and cellular localization.
In this study we investigated the localization of α2,3(N)-sialyl-
transferase (ST3Gal III) by immunocyto- and -histochemical
methods. Since mass expression and secretion of glycosyltransfer-
ases is well afforded by truncating them to soluble forms (Colley
et al., 1989), we used the powerful baculovirus-based expression
system to obtain a pure soluble form of rat ST3Gal III to use as
antigen (Gosselin et al., 1994). In addition, we also used the
strategy of expressing the glycosyltransferase antigen as a
β-galactosidase fusion-protein in E.coli to obtain non-glycosylated
peptide antigens for the induction of protein specific polyclonal
antisera (Watzele et al., 1991; Berger et al., 1993) since presence
of carbohydrate specific antibodies could cause misleading results
(Feizi and Childs, 1987). The characterization of these newly
developed antibodies led to the detection of an unexpected
crossreactivity of antibodies directed against ST3Gal III with the
β-galactosidase portion of the fusion-protein. We further present
evidence that this phenomenon may be common and does not
restrict specificity of the antiserum to the respective glycosyltrans-
ferase. We used the antibodies for immunohistochemistry to show
evidence for Golgi and post-Golgi localization of ST3Gal III in rat
kidney tubular epithelial cells.
Results
Antibodies to recombinant soluble rat ST3Gal III
A truncated form of rat ST3Gal III (see Figure 1) was expressed
as a soluble recombinant enzyme in Sf9 cells using the
baculovirus expression system (Gosselin et al., 1994). The
enzyme was purified on SP-Sepharose and CDP-ethanolamine-
Sepharose to homogeneity and shown to exhibit a catalytic
activity of 20 U/mg using Galβ1–3GlcNAcβ-O(CH2)8COOMe
as an acceptor substrate. The enzyme was injected into rabbit 1
to induce a polyclonal antiserum (anti-rat ST3Gal III) as
described in Materials and methods. The antiserum was tested by
ELISA (Figure 2d) against soluble rat ST3Gal III (Figure 2d) as
well as against human ST3Gal III-βgalactosidase fusion protein
(not shown) and by immunofluorescence on COS-1 cells
transfected with pcDNA-ST3Gal III. While only a low antiserum
titer of 1:960 was measured, bright endoplasmic reticulum-asso-
ciated fluorescence was detected in transiently transfected COS-1
cells (Figure 3b, inset). However, typical Golgi patterns were
missing. From these data we concluded that (1) an antiserum was
obtained specifically recognizing ST3Gal III, (2) the antiserum
raised against a soluble rat enzyme crossreacted with its human
homolog, and (3) that this truncated form essentially consisting
of the catalytic domain was not very immunogenic. The absence
of Golgi patterns in transfected cells could either be ascribed to
poor transport competence out of the endoplasmic reticulum in
COS cells or inability of the antiserum to recognize Golgi-
associated forms. Nevertheless, using ST3Gal III fusion-protein
affinity purified antibodies (anti-rat ST3Gal III f), we were able
to detect weak staining of the Golgi apparatus in HepG2 cells (not
shown). On rat tissue sections, however, purified anti-rat ST3Gal
III f antibodies stained the Golgi apparatus in epithelial cells of
proximal renal tubules and brush border-associated elements (not
shown). Altogether, the fluorescent signals were considered too
weak to warrant photodocumentation. These data supported
findings reported previously that immunogenicity of glycosyl-
transferases is associated with the least conserved domain, i.e.,
the stem region (Watzele et al., 1991; Berger et al., 1993). Thus,
we decided to raise antibodies to the full length enzyme as a
β-galactosidase linked fusion-protein.
Construction of the α2,3(N)-sialyltransferase expression
vector (pEX2-ST3Gal III) and expression of the
β-galactosidase-α2,3(N)-sialyltransferase fusion-protein
(ST3Gal III-FP)
Total RNA was isolated from Jurkat cells (human T cell line) and
the mRNA fraction reverse transcribed to cDNA by oligo dT
primers. The ST3Gal III sequence was amplified by PCR using
specific primers flanking the full length of the coding region.
Interestingly, Jurkat cells expressed two forms of ST3Gal III, one
bearing a deletion of 48 bp from nucleotide position 120 to 167.
Although this proved to be a finding which could be reproduced
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Fig. 2. Characterization of the different antibodies by ELISA. (a) Crossreactivity of anti-hST3Gal III immune serum with β-galactosidase (b-gal), truncated
recombinant rat ST3Gal III (rat ST3Gal III) and β-galactosidase-ST3Gal III fusion-protein. (b) Crossreactivity of anti-hST3Gal III fb toward β-galactosidase,
fusion-protein and rat ST3Gal III. (c) Crossreactivity of anti-β-gal towards β-galactosidase (b-gal) and fusion-protein. (d) Reactivity of anti soluble rat ST3Gal III
immune- and preimmune serum toward soluble rat ST3Gal III.
from RNA extractions of several different cell lines we decided
not to explore it further. The form of the ST3Gal III PCR product
harboring the deletion was used for subsequent cloning into
pUC18 vector. Sialyltransferases share two regions of homology
(Sasaki et al., 1993) which might lead to crossreacting antibodies.
The ST3Gal III DNA sequence contains an internal XhoI
restriction site (nucleotide position 779). XhoI was used in the
subsequent cloning of ST3Gal III into the expression vector
pEX2 to truncate the ST3Gal III DNA at its 3′ end. Thus, the
sequence coding for one of the conserved regions was eliminated.
Figure 1 shows (a) a scheme of the predicted full-length ST3Gal
III protein from human placenta as reported by Kitagawa and
Paulson (1993); (b) the corresponding DNA sequence; (c) the
β-galactosidase-ST3Gal III DNA construct with the PCR-cloned
P.C.Burger et al.
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Fig. 3. Expression of human ST3Gal III in COS cells and immunodetection using an antiserum to recombinant soluble rat ST3Gal III. (a) Mock transfected COS
cells stained with anti-rat ST3Gal III; (b) COS cells transiently transfected with pcDNA-ST3Gal III and stained with anti-rat ST3Gal III; transfected cells depict
ER staining only (see inset). Scale bar, 20 µm.
form of ST3Gal III, harboring the 48 bp deletion, which led to the
production of the antigen used for the immunization of rabbit 2;
and (d) the truncated form of rat ST3Gal III used for expression
in Sf9 cells.
The β-galactosidase ST3Gal III fusion-protein (ST3Gal
III-FP) was produced in E.coli following transformation and
induction. This heterologously expressed ST3Gal III-FP had a
molecular weight of about 160 kDa. After separation of the
proteins by SDS–PAGE, the band representing the fusion-protein
was cut out, and the protein was eluted and analyzed for purity.
Electrophoretically pure fractions (not shown) were then used for
the immunization of rabbit 2 as described in Materials and
methods. Another rabbit (rabbit 3) was immunized with a
fusion-protein missing the first 29 N-terminal amino acids of
ST3Gal III (but without deletion). Although specific, the
antiserum failed to stain the enzyme in tissue cultured cells and
was not used further.
Characterization of the antibodies against human ST3Gal III
The polyclonal antibodies against human ST3Gal III (anti-
hST3Gal III) obtained by immunizing rabbit 2 with this
heterologously expressed ST3Gal III-FP were characterized first
by ELISA. The immune serum had a titer of about 1:8100 toward
the coated ST3Gal III-FP, whereas binding of the preimmune
serum (PIS) was negligible at the same dilution (not shown). The
anti-hST3Gal III antiserum exhibited a lower titer towards
purified β-galactosidase and the truncated recombinant form of
rat ST3Gal III (Figure 2a). Since use of this antiserum to localize
ST3Gal III in tissue specimens was intended, we prepared a
fraction of affinity purified antibodies devoid of antibodies
specific for β-galactosidase. The purification scheme (Figure 4)
involved two affinity purification steps, first on the fusion-protein
column (yielding anti-hST3Gal III f) followed by a β-galacto-
sidase column (yielding anti-hST3Gal III fb). Antibodies retained
on the β-galactosidase column were designated anti-β-gal. The
corresponding binding curves are shown on Figure 2b and c and
were as expected. As shown in Figure 5, these antibodies were
tested by immunoblotting for reactivity toward ST3Gal III
fusion-protein (slots 1, 4, 8), E.coli β-galactosidase (slots 2, 5, 7),
and recombinant rat ST3Gal III (slots 3, 6, 9). The anti-hST3Gal
III f (slots 1, 2, 3) reacted with all three antigens as predicted from
the ELISA (Figure 2a). The anti-hST3Gal III fb (slots 7, 8, 9)
Localization of α2,3(N)-sialyltransferase
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reacted with the fusion-protein (slot 8) and the rat ST3Gal III
(slot 9), but not with β-galactosidase (slot 7), indicating efficient
removal of these antibodies. Surprisingly, anti-β-gal antibodies
(slots 4, 5, 6) also recognized the purified recombinant rat ST3Gal
III (slot 6), indicating some sort of crossreactivity between
β-galactosidase and the sialyltransferase portion of the fusion-
protein. These results were confirmed by an independent method
consisting of heterologous expression of the antigen (Jurkat
cell-derived full length ST3Gal III) in COS cells followed by
immunofluorescent staining of the expressed antigen. Figure 6
shows a panel of mock and pcDNA-ST3Gal III transfected COS
cells. The anti-hST3Gal III f recognized endogenous Golgi-
localized ST3Gal III in mock transfected COS cells (Figure 6a)
and an overexpressed form also strongly decorating the Golgi
apparatus (arrowhead) and ER-structures as indicated by the
staining of the nuclear envelope (arrow, Figure 6c). To our
surprise, removal of antibodies to β-galactosidase abrogated
Golgi staining irrespective of its origin, i.e., both endogenous and
transfected (Figure 6b), but this same anti-hST3Gal III fb fraction
was able to recognize an ER-associated form of the transfected
ST3Gal III (Figure 6d,e). Conversely, the antibodies to ST3Gal
III eluted from the β-galactosidase column (anti-β-gal anti-
bodies) were able to stain the Golgi apparatus (Figure 6f) in
addition to some ER-associated forms (arrow). From these data
we concluded that Golgi staining was conferred by ST3Gal III
specific antibodies that crossreact with a common epitope also
present on β-galactosidase. Immunoblots (Figure 5, slot 10) using
the anti-hST3Gal III fb fraction on mock transfected COS cell
lysate revealed one band at ∼50 kDa, which may correspond to a
mature and glycosylated, but denatured form of ST3Gal III since
no Golgi staining was observed using this antibody fraction
(Figure 6b). In ST3Gal III transfected COS cells (Figure 5, slot
11), the fb fraction identified additional forms at ∼40 kDa. All
these signals could be completely absorbed by addition of
purified recombinant rat ST3Gal III (Figure 5, slot 12) while the
fusion-protein was still recognized (slot 13). We attribute this
reactivity to the recognition of denatured Golgi-associated forms
of ST3Gal III (50 kDa) and not completely matured ER-
associated forms (40 kDa). From these data we surmise that the
antibody fraction fb specifically recognizes an epitope of ST3Gal
III which may not be accessible in its native, Golgi-associated
conformation. Conversely, those antibodies that crossreacted
with β-galactosidase react with a conformation-independent
epitope. This latter is likely to be associated with the N-terminus
of ST3Gal III since a ST3Gal III construct from which the
N-terminus was deleted was not able to induce an antiserum
recognizing the Golgi apparatus but which also stained the ER of
ST3Gal III-transfected COS cells (antiserum of rabbit 3, not
shown).
We were then interested whether antisera previously raised to
β-galactosidase fusion-proteins reacted in a similar way. We
investigated two polyclonal antisera raised against a β-galactosi-
dase-β1,4-GT fusion-protein (Watzele et al., 1991) and a
β-galactosidase-ST6Gal I fusion-protein (Berger et al., 1993),
respectively. Again, by purification on the β-galactosidase column
we were able to isolate a β-galactosidase specific fraction of the
antiserum to β1,4-GT fusion-protein which specifically stained the
Golgi apparatus in HeLa cells; this staining could be completely
blocked by addition of purified human milk β1,4-GT (not shown).
Similarly, a β-galactosidase specific fraction of the antiserum to
ST6Gal I fusion-protein also specifically stained the Golgi
apparatus in HeLa cells (not shown). Dot blots then confirmed
these findings and also showed that the antibodies to β-galactosi-
Fig. 4. Scheme of the affinity purification steps of anti-hST3Gal III antisera.
Antibodies retained on the fusion-protein column (anti-hST3Gal III f) were
subsequently affinity purified on a β-galactosidase column. The flow through
of this column (anti-hST3Gal III fb) was specific for the ST3Gal III part of
the fusion-protein. Antibodies retained on the β-galactosidase column
(anti-β-gal) were also characterized.
Fig. 5. Immunoblots using different antibody fractions. For technical details,
see Materials and methods. Experiments from different blottings were
aligned for the marker positions as indicated. Anti-hST3Gal III f (slots1, 2,
3), anti-β-gal (slots 4, 5, 6), and anti-hST3Gal III fb (slots 7, 8, 9, 10, 11)
were probed for crossreactivity with fusion-protein (slots 1, 4, 8),
β-galactosidase (2, 5, 7), rat ST3Gal III (3, 6, 9) and lysate of mock
transfected (slot 10) and ST3Gal III-transfected (slot 11) COS cells.
Anti-hST3Gal III fb was preabsorbed with rat ST3Gal III and tested for the
remaining reactivity towards ST3Gal III-transfected COS cells (slot 12) and
fusion-protein (slot 13).
dase crossreacted only with the glycosyltransferase portion of the
fusion-protein against which they were raised but not with another
one, e.g., the β-galactosidase specific fraction of the antiserum to
β1,4-GT fusion protein did not crossreact with the β-galactosidase-
ST6Gal I fusion-protein (not shown). Importantly, in the case of the
antiserum to β1,4-GT fusion-protein, best Golgi staining was
P.C.Burger et al.
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Fig. 6. Immunofluorescence microscopy of transiently transfected COS cells. (a) Mock transfected COS cells labeled with anti-hST3Gal III f. (b) Mock
transfected COS cells labeled with anti-hST3Gal III fb; nuclear staining but no Golgi or ER signal was observed. The finding of nuclear staining was not further
investigated. (c) ST3Gal III transfected COS cells labeled with anti-hST3Gal III f. This antibody recognized the overexpressed protein in an enlarged Golgi
apparatus (arrowhead) and in the nuclear envelope (arrow) of the cells. (d, e) ST3Gal III transfected COS cells labeled with anti-hST3Gal III fb; only ER
structures are stained. (f) ST3Gal III transfected cells labeled with anti-β-gal. Anti-β-galactosidase antibodies also recognized overexpressed ST3Gal III (arrow).
(g) ST3Gal III transfected COS cells labeled with preimmune serum. Scale bar, 20 µm.
obtained with a fraction of anti-fusion-protein antiserum purified
on immobilized human milk β1,4-GT (not shown). From these
data we conclude that three antisera to three different β-galactosi-
dase-glycosyltransferase fusion-proteins, respectively, contain a
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Fig. 7. Localization of ST3Gal III to the Golgi apparatus. Double immunofluorescence microscopy with (a) anti-hST3Gal III f and (b) monoclonal mouse
antibody against β1,4-galactosyltransferase (mAb 36/118) for the localization of ST3Gal III in HeLa cells. Localization of ST3Gal III in (c) hamster CHO- and
(d) rat IEC-cells. Scale bar, 20 µm.
fraction that crossreacted specifically with an epitope located on
the β-galactosidase portion of the respective fusion-protein.
Nevertheless these antibodies are specific reagents for the
respective glycosyltransferase portion and thus considered suitable
for immunohistochemical applications.
Application of anti-hST3Gal III antibodies for
immunocytochemical localization in tissue cultured cells
ST3Gal III is localized in the Golgi apparatus of human HeLa
cells as shown by colocalization of ST3Gal III with β1,4-GT by
double immunofluorescence microscopy using the polyclonal
anti-hST3Gal III f and the monoclonal anti-β1,4-GT antibodies
(Berger et al., 1986), respectively (Figure 7a,b). ST3Gal III
colocalized with β1,4-GT also in other human cell lines, namely
CaCo (colon adenocarcinoma), ECV304 (endothelial cell line),
fibroblasts, and HepG2 (not shown).
Localization of ST3Gal III in rat kidney tissue
In immunofluorescence microscopy on cultured cells, anti-
hST3Gal III f also stained the Golgi apparatus of hamster CHO
(Figure 7c) and rat IEC cells (Figure 7d), which was not
surprising since rat and human ST3Gal III share 97% homology
on the amino acid level (Kitagawa and Paulson, 1993). The
antibodies proved their usefulness for immunofluorescence
microscopy on rat tissue sections. We performed localization
studies of this glycosyltransferase in kidney since sialyltransfer-
ases are highly expressed in kidney as shown by Northern
analysis (Wen et al., 1992). ST3Gal III was localized to the Golgi
apparatus of glomerular, tubular (Figure 8a), and interstitial cells.
In addition, however, an unexpected location of ST3Gal III at the
apical membrane of proximal convoluted tubules (PCT) and of
single cells in connecting tubules (CNT) and collecting ducts
(CD) was observed. Comparison of the apical ST3Gal III staining
with the staining of H+ATPase revealed on the one hand a striking
similarity of localization of the enzyme and the proton pump at
the brush border of PCT cells, and on the other hand the
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confinement of apical ST3Gal III staining in CNT and CD to
H+ATPase-positive intercalated cells (Figure 8b). All of the
observed staining was completely abolished by preabsorption of
the antiserum with the respective antigen (Figure 8c), indicating
that the staining was specific. Furthermore, control antisera that
also contained antibodies to bacterial β-galactosidase did not
stain, but the antiserum to recombinant soluble rat ST3Gal III
produced identical results (not shown).
In order to localize ST3Gal III more precisely in the apical
region of PCT, we combined the immunostaining of ST3Gal III
with a staining of actin filaments using rhodamine-conjugated
phalloidin (Figure 9a,b). The actin filament-rich microvilli were
evenly stained by the phalloidin-conjugate, revealing them as
morphologically intact. Within the brush border, ST3Gal III
staining was strongest at the base of the microvilli, although a
faint staining was detected along the entire microvilli. The same
staining pattern was found also for H+ATPase. Immunostaining
of consecutive sections with anti-hST3Gal III serum and a
specific antibody to rat ST6Gal I (Bosshart and Berger, 1992),
respectively, revealed a clear Golgi localization of both sialyl-
transferases (Figure 9c,d). In contrast to ST3Gal III, no signifi-
cant apical expression of ST6Gal I was detected.
Discussion
In this report, we describe production and characterization of
antibodies to recombinant human Gal-β1,3(4) GlcNAc
α2,3(N)-sialyltransferase (ST3Gal III) by different biochemical
and cell biological methods. ST3Gal III shares two regions of
homology with other sialyltransferases (Wen et al., 1992; Sasaki
et al., 1993; Datta et al., 1995). These two peptide stretches, also
called sialylmotifs (see Figure 1), were found on all the
sialyltransferases cloned so far and seem to be characteristic for
the sialyltransferase family. These sialylmotifs are potential
crossreactive epitopes for our antibodies. One of these sialylmo-
tifs is located at the C-terminus of ST3Gal III. To eliminate this
C-terminal part in the recombinant protein, we took advantage of
an internal XhoI restriction site in the ST3Gal III nucleotide
sequence and used a C-terminal truncated form for the construc-
tion of the ST3Gal III expression vector. The other sialylmotif
seemed not to be recognized by our anti-hST3Gal III antibodies.
Whereas preincubation of the anti-hST3Gal III antibodies with
the corresponding antigen (ST3Gal III-FP) completely abolished
a specific immunofluorescent signal, preincubation with another
sialyltransferase fusion-protein (ST6Gal I fusion-protein; Berger
et al., 1993), bearing the respective sialylmotif, did not alter
binding of the antibodies (not shown). These results indicate that
antibodies to ST3Gal III do not crossreact with ST6Gal I and can
thus be considered monospecific. The hitherto known and cloned
sialyltransferases have recently been reviewed: except for the
presence of the sialylmotifs little homology has been detected
(Harduin-Lepers et al., 1995). Thus, crossreactivities among
different sialyltransferases are not likely to occur since the
sialylmotif did not appear to be antigenic whereas interspecies
crossreactivity was strong since on the amino acid level, ST3Gal
III is conserved to a degree of 97% between rat and human
(Kitagawa and Paulson, 1993). Weinstein and colleagues purified
the homologous enzyme from rat liver to homogeneity (Weins-
tein et al., 1982) and obtained a single band with a molecular
weight of 44 kDa. By immunoblotting of COS cell lysates (Figure
5), our antibodies detected a single band at around 50 kDa.
Unglycosylated ST3Gal III has a theoretical molecular weight of
about 43–44 kDa with two potential N-glycosylation sites. The
observed difference in the molecular weight may be due to
different glycosylation by COS cells and the possibility that the
form identified by Weinstein et al. might have been processed.
Since the homology of ST3Gal III among different species
seems to be quite high, it was not surprising that the antibodies
showed crossreactivity with the corresponding enzymes of rat
IEC-, mouse L-, and simian COS-1 cells. In all the tested human
cell lines, ST3Gal III colocalized with galactosyltransferase,
indicating that this enzyme, like ST6Gal I (Roth et al., 1985), is
located in the trans Golgi/TGN of these cells. Independent
evidence for colocalization of both α2,3- and α2,6(N)-sialyl-
transferase has been obtained by transfection of the latter in CHO
cells; thereby, the linkages of terminal sialic acid residues were
changed partially from 2–3 to 2–6 positions (Lee et al., 1989).
Unexpected, however, was the observation made by immuno-
fluorescence microscopy on rat kidney tissue. In the proximal
convoluted tubule and in intercalated cells of the connecting
tubule and the collecting duct, ST3Gal III was localized in the
Golgi and additionally in the region of the apical membrane
(Figure 8). This staining corresponds to a bona fide localization
of ST3Gal III since conventional controls accepted in immunocy-
tochemistry such as abolition of staining by absorption with
antigen support this assertion. Moreover, use of another antiser-
um raised against a different form of the enzyme (soluble, Sf9 cell
expressed rat enzyme) produced identical staining patterns. In
addition, crossreactivity with carbohydrate antigens is very
unlikely to occur with antibodies against peptide antigens. We
were interested in assessing the possibility that antibodies to
β-galactosidase present in our antibody preparations could
crossreact with an unrelated protein. Although this possibility
could not formally been excluded, we presented evidence that
those antibodies which specifically decorated the Golgi apparatus
reacted there with ST3Gal III but also crossreacted with
β-galactosidase, which could be due to a common epitope in the
link region from β-galactosidase to ST3Gal III.
At the light microscopic level the exact nature of the apical
structures positive for the presence of ST3Gal III (cell surface or
subapical vesicles) can not be clearly defined. In the proximal
tubule almost complete colocalization at the light microscopic
level of ST3Gal III with H+ATPase, a protein known to be located
in the brush border membrane (Brown et al., 1988) as well as in
subapical vesicles suggest the occurrence of ST3Gal III at both
locations. This post-Golgi localization for a sialyltransferase is
not without precedent: Taatjes and colleagues reported the
localization of ST6Gal I in post-Golgi vesicles, brush border and
basolateral membranes, multivesicular bodies and lysosome-like
structures of absorptive enterocytes. In addition they found
ST6Gal I in mature mucus droplets and in the plasma membrane
of goblet cells (Taatjes et al., 1988). Interestingly, in kidney
tubular epithelial cells ST6Gal I did not colocalize at this
post-Golgi site with ST3Gal III indicating a sorting mechanism
between these two glycosyltransferases.
Brada reported a similar unexpected location of glucosidase II
in pig kidney epithelial cells (Brada et al., 1990): Glucosidase II
previously known as a resident ER enzyme, was found as a
sialoglycoprotein predominantly in post-Golgi compartments of
proximal tubules similar to those described here for the presence
of ST3Gal III. Also in this case, the functional implication of such
a localization remained obscure.
The luminal cell surface of kidney proximal tubular cells,
similar as in intercalated cells, is highly glycosylated and is
subjected to a very high turnover (for review, see Brown, 1989).
Sialyltransferases in the region of the luminal membrane might
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Fig. 8. Overview of immunolocalization of ST3Gal III on serial cryosections or rat kidney. (a) Immunohistochemistry with affinity purified anti-hST3Gal III
antiserum (fraction antiST3Gal III f; see text) produces a staining in epithelial cells of proximal tubules (P) and connecting tubules (asterisk) in some cells of the
glomeruli (G) and in interstitial cells. In epithelial cells, an intracellular staining at the typical perinuclear Golgi-localization can be recognized (small arrows).
Luminal staining of epithelial cells is also detected (arrowheads). (b) Luminal ST3Gal III can be partially colocalized with H+ATPase which is found in proximal
tubular cells at the base of the apical brush border (large arrowhead) and in intercalated cells (small arrowheads). (c) Absorption with ST3Gal III-β-galactosidase
fusion protein of anti-hST3Gal III antiserum completely prevented immunostaining of a consecutive kidney section. Scale bar, 50 µm.
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Fig. 9. Comparison of the proximal tubular localization of ST3Gal III with actin filaments and of ST3Gal III with ST6Gal I. (a, c) The ST3Gal III specific
antiserum decorates intracellularly a juxtanuclear (Golgi) region and apically the brush border where staining appears strongest at the base. (b) Co-staining of the
section in (a) for actin filaments depicts the brush border in their full width. (d) Staining of a section consecutive to (c) for ST6Gal I reveals a similar Golgi
localization of the enzyme and its absence in the apical region. Scale bar, 50 µm.
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have a function in the resialylation of recycling cell surface
glycoproteins. Such a resialylation process in the endocytotic
compartment has been well documented in cultured cells (Snider
and Rogers, 1985; Duncan and Kornfeld, 1988). Further work is
needed to define the exact localization of ST3Gal III at these
post-Golgi sites and to identify any corresponding functional
implications.
Materials and methods
Materials
Polyclonal antibodies to rat ST6Gal I (Bosshart and Berger, 1992)
and monoclonal antibodies to β1,4-GT (Berger et al., 1986) were
described previously. Monoclonal antibodies to H+-ATPase were
kindly provided by S. Gluck (Hemken et al., 1991).The origins
of commercially available material are indicated below. All cell
lines used were from ATCC (Rockville, MD). Chemicals were of
analytical grade purity and obtained from Fluka (Buchs, Switzer-
land).
Construction of α2,3N-sialyltransferase vectors
Rat α2,3(N)-sialyltransferase. A soluble and exported form of the
α2,3(N)-sialyltransferase from rat liver was cloned in baculovi-
rus as described previously by Gosselin et al. (1994).
Human α2,3(N)-sialyltransferase.Total RNA from the Jurkat
cell line (T cell line) was isolated by the RNAgent kit (Promega,
Madison, WI). Double stranded cDNA was synthesized by
reverse transcription using oligo dT primers synthesized by
Microsynth (Windisch, Switzerland) and Superscript RT poly-
merase from Gibco (Grand Island, NY). Oligonucleotides
(Microsynth) corresponding to the flanking regions of the full
length of the ST3Gal III sequence were used as specific primers
for PCR amplification (“ST3Gal III/Nco.up: 5′-ggccATGG-
GACTCTTGGTATTTGT-3′ and “ST3Gal III/Xho.down:
5′-gcctcgagTCAGATGCCACTGCTTA-3′). These primers con-
tained at their 5′ ends additional consensus sequences for the
restriction enzymes NcoI and XhoI (small letters), respectively.
The PCR procedure conditions were 95C for 40 sec, 55C for
55 s, and 72C for 90 s for denaturation, annealing and
polymerization, respectively. The obtained 1.1 kb band was
excised from the 1% low melt agarose gel and used for another
round of amplification under the same conditions. After the
second round, the DNA in the excised band was isolated from the
gel by the Geneclean II kit (BIO 101 Inc., La Jolla, CA). This
cDNA was treated with Klenow Fragment (Promega, Madison,
WI) and ligated into SmaI (Promega) cleaved vector pUC18
(pUC18-ST3Gal III). This plasmid was transfected into compet-
ent XL1-blue cells (Stratagene, La Jolla, CA). Since ST3Gal III
contains an internal XhoI restriction site (nucleotide position
779), we used the 3′ end (C-terminal) truncated form of double
digested NcoI/XhoI pUC18-ST3Gal III for subcloning into SmaI
cleaved expression vector pEX2 (Clontech, Palo Alto, CA).
Inframe cloning of ST3Gal III to the β-galactosidase sequence of
the expression vector as a β-galactosidase-α2,3(N)-sialyltrans-
ferase fusion-protein (pEX-ST3Gal III-FP) was checked by
sequencing with the T7 sequencing Kit from Pharmacia (Uppsa-
la, Sweden).
For the expression of ST3Gal III in COS-7 cells a completely
sequenced, full length PCR product was cloned into EcoRV
cleaved pcDNAI (Invitrogen, San Diego CA) further referred to
as pcDNAI-ST3Gal III.
Production and purification of soluble recombinant rat
ST3Gal III
Recombinant baculovirus was used to infect Sf9 cells, grown at
28C in EX-CELL 400 medium (JHR Biosciences) supplem-
ented with 5% FCS to a cell density of 2 ×106. The multiplicity
of infection was about 20. Sixty hours postinfection the
conditioned medium was spun, filtered through 0.8 µm mem-
brane, and 10-fold concentrated using a spiral ultrafiltration
cartridge (YM30, Amicon). All further purification steps were
carried out at 4C. The enzyme solution was loaded onto a
SP-Sepharose column (Fast-flow, Pharmacia), equilibrated with
buffer A (50 mM Na cacodylate, pH 6.5). The column was
washed with buffer A and eluted with buffer A containing 500
mM NaCl, 20% glycerol (v/v). The eluate was diluted with buffer
A to 150 mM NaCl, 6% glycerol and loaded onto a CDP-ethano-
lamine-Sepharose affinity column, equilibrated with buffer A
containing 150 mM NaCl. After washing the column with
equilibration buffer, the enzyme was eluted with buffer A
containing 1 M NaCl, 1 mg/ml CDP. The eluate was brought to
50 mM Na cacodylate, pH 6.5, 250 mM NaCl, 250 µg/ml CDP.
Aliquots of the enzyme (6 U/ml) were stored at -80 C.
Production and purification of ST3Gal III-FP
Plasmid pEX2-ST3Gal III-FP was transformed into the tempera-
ture sensitive E.coli strain N4830–1 (Clontech). After induction
of protein expression by temperature shift, cells were harvested
by centrifugation and lysed, and their inclusion bodies, containing
the ST3Gal III-FP were purified as described previously (Berger
et al., 1993). ST3Gal III-FP was obtained by fractionation of the
inclusion bodies on a 7.5% SDS–polyacrylamide gel, excision of
the ST3Gal III-FP band from the gel and elution of the
fusion-protein using the biotrap from Schleicher & Schuell
(Dassel, D) with 15 mM NH4HCO3 buffer.
Induction of antibodies and their purification.
Antiserum to soluble rat ST3Gal III. Purified antigen (62.5) µg of
emulsified with complete Freund adjuvant (Sigma, St. Louis,
MO/USA) was subcutaneously injected into rabbit 1 (New
Zealand White) followed by five boost injections with incomplete
adjuvant every fortnight.
Antiserum to human ST3Gal III-FP. An analogous scheme to
immunize rabbits 2 and 3 was applied as for the rat ST3Gal III,
except that 108 µg fusion-protein was injected at a time.
The third rabbit was injected a modified form of the
fusion-protein (see results). For construction of the affinity
columns 0.8 mg of ST3Gal III-FP and 0.9 mg of β-galactosidase
(Sigma) were immobilized on Affi-Gel 10 and 15 (Bio-Rad,
Richmond, CA), respectively, according to the user’s manual.
The ST3Gal III-FP column was equilibrated with buffer H
(100 mM HEPES, pH 7.9) at 4C. All three antisera were purified
on the ST3Gal III-FP column by loading them five fold diluted
in the same buffer H. After shaking overnight, the column was
washed with buffer H containing 500 mM NaCl. Bound
antibodies were eluted with 100 mM glycine-HCl pH 2.8,
immediately neutralized in 1 M HEPES pH 10, and dialyzed
against Tris buffered saline (TBS). The following designations
are used. On the ST3Gal III-FP column affinity purified
antibodies derived from antiserum to recombinant soluble rat
ST3Gal III: anti-rat ST3Gal III f; from antiserum to ST3Gal
III-FP: anti-hST3Gal III f; also see scheme (Figure 1). An
antibody fraction of anti-hST3Gal III f was then loaded on a
β-galactosidase column that was previously equilibrated with
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TBS. After shaking overnight at 4C the flow through of this
column was collected (anti-hST3Gal III fb) and concentrated in
a 100 kDa cut-off Centricon (Amicon, Beverly, MA/USA). After
washing the β-galactosidase column with TBS/500 mM NaCl,
retained antibodies (anti-β-gal) were eluted with 100 mM
glycine-HCl pH 2.8, immediately neutralized in 1 M Tris pH 10,
dialyzed against TBS, and concentrated with Centricon 100.
Figure 1 shows a scheme of the different fractions of antibodies
to ST3Gal III.
ELISA
Immunoplates (Nunc Maxisorp, Gibco) were coated overnight at
4C with 0.37 µg fusion-protein, 0.4 µg β-galactosidase and
1.2 µg rat ST3Gal III. The protein concentration was inversely
related to the length of the corresponding protein to match for the
number of epitopes. The following day, antibodies diluted in
100 mM NaCl, 0.05% Tween 20 were incubated in the indicated
dilutions for 90 min at room temperature. After two washes with
NaCl/Tween 20, 1:2000 diluted horseradish peroxidase (HRP)
coupled with goat anti-rabbit IgG (Bio-Rad) was incubated for
90 min. After two final washes with NaCl/Tween 20, substrate
solution containing 50 mM Na2HPO4, 25 mM citric acid, 0.12%
(v/v) H2O2, and 0.04% (w/v) 1,2-phenylenediamine was added.
The reaction was stopped by the addition of 1.25 M H2SO4.
Optical density was measured in an ELISA reader at 492 nm.
Transfection of COS cells
COS-7 or COS-1 cells were grown to 50% subconfluency either
in 100 mm dishes or for immunofluorescence microscopy on
glass cover slips in 33 mm dishes. The cells were transfected for
transient protein expression with 3 µg (100 mm) and 0.5 µg (33
mm) plasmid pcDNAI-ST3Gal III (=ST3Gal III transfected cells)
or pcDNAI alone (=mock transfected cells) using lipofectin
(LipofectAMIN from Gibco) as indicated by the manufacturer.
After 48 h cells were lysed for immunoblots or treated as
described below.
Immunofluorescence microscopy on cultured cells
Cells were cultured at 37C on glass coverslips to subconfluency.
Before staining, they were washed with phosphate-buffered
saline (PBS), fixed for 10 min by prewarmed (37C) 3.5% (w/v)
paraformaldehyde in Hanks Balanced Salt Solution (GibcoBRL).
All further steps were carried out at room temperature. Cells were
rinsed three times with PBS, quenched for 10 min with 20 mM
glycine in PBS, rinsed again three times with PBS, and
permeabilized for 30 min by 0.1% (w/v) saponin in PBS
(sap/PBS). The permeabilized cells were then incubated for 1 h
at room temperature with suitably diluted first antibodies, washed
three times with sap/PBS, and covered 1 h at room temperature
with 50 fold diluted Texas red (TR) conjugated goat anti rabbit
antibodies (Organon Teknika–Cappel, Turnhout, B) or fluores-
cein-isothiocyanate (FITC) conjugated goat anti-mouse anti-
bodies (Dako). After three washes with sap/PBS the coverslips
were mounted on glass slides with Mowiol-N-propyl-gallate
(Berger et al., 1993).
Immunoblot analysis
Subconfluent HeLa and transfected COS cells from 100 mm petri
dishes were harvested and lysed during 45 min at 4C in PBS
containing 1.5% Triton X-100 and 1 mM phenylmethansulfonyl-
fluoride (PMSF). Lysates were cleared by centrifugation for
15 min at 15,000 × g. For immunoblot analysis, proteins from
lysates and purified proteins were separated by SDS–polyacryl-
amide gel electrophoresis (SDS–PAGE) on a 10% gel and
electrotransferred to a nitrocellulose membrane. The membrane
was blocked with blocking buffer (1% milk powder, 15 mM
NaCl, 5 mM Tris, 0.1% NP-40 pH 7.5) at 4C overnight. The blot
was then probed 1 h with suitably diluted first antibodies, washed
three times 20 min with blocking buffer, incubated 1 h with
horseradish peroxidase (HRP)-conjugated anti rabbit Ig G
(Sigma) 1:10,000 diluted in blocking buffer, and washed again
three times with blocking buffer. The blot was developed with the
“enhanced chemiluminescence (ECL) detection kit (Amersham,
Buckinghamshire, UK).
Immunohistochemistry on rat kidney
Rats (Sprague Dawley) were anesthesized with thiopental 100
mg/kg body weight, injected intraperitoneally, and perfused
retrogradely at a pressure of 1.38 hp through the abdominal aorta
with a fixative of 3% paraformaldehyde and 0.05% picrinic acid
in a 6:4 mixture of 0.1 M cacodylate buffer (pH 7.4, adjusted to
300 mM with sucrose) and 10% hydroxyethyl starch (HAES
steril). After 5 min of fixation, the fixative was replaced by
perfusion for 5 min with cacodylate buffer.
Slices of fixed kidneys were frozen in liquid propane and
cooled by liquid nitrogen. Sections of 3 µm were cut at -22C in
the cryomicrotome, mounted on chromalum/gelatine-coated
glass slides, thawed, and stored in cold PBS until use.
For immunofluorescence staining, sections were preincubated
for 10 min with 3% milk powder in PBS containing 0.3% Triton
X-100. They were then covered overnight at 4C with primary
antibodies diluted as indicated below. The sections were rinsed
three times prior to incubation for 1 h at 4C with secondary
antibodies and/or rhodamine-conjugated phalloidin. All immu-
nochemicals were diluted in PBS/3% milk powder. Dilutions
were 1:500 for the anti-hST3Gal III f antiserum, 1:20 for the
anti-H+ATPase antibody, 1:50 for swine anti rabbit IgG conju-
gated to FITC (Dakopatts, Glostrup, Denmark), 1:200 for goat
anti-mouse IgG conjugated to Cy3 (Jackson ImmunoResearch
Laboratories, West Grove, PA), and 1:100 for phalloidin-rhoda-
mine (Molecular Probes Inc., Eugene, OR). After being rinsed
with water the sections were coverslipped using DAKO-Glycer-
gel (Dakopatts) plus 2.5% 1,4-diazabicyclo{2.2.2}octane
(Sigma) as a fading retardant. All immunofluorescence prepara-
tions were studied with a Polyvar (Reichert-Jung) microscope
equipped for epifluorescence and using narrow-band filter
systems for FITC and Cy3.
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pcDNA vector containing full length human ST3Gal III cloned
from the Jurkat cell line.
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